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http://dx.doi.org/10.1016/j.stemcr.2017.03.026SUMMARYTaxanes are amainstay of treatment for breast cancer, but resistance oftendevelops followed bymetastatic disease andmortality. Aiming to
reveal the mechanisms underlying taxane resistance, we used breast cancer patient-derived orthoxenografts (PDX). Mimicking clinical
behavior, triple-negative breast tumors (TNBCs) fromPDXmodelsweremore sensitive to docetaxel than luminal tumors, but they progres-
sively acquired resistance uponcontinuousdrug administration.Mechanistically,we found that aCD49f+ chemoresistant populationwith
tumor-initiating ability is present in sensitive tumors and expands during the acquisition of drug resistance. In the absence of the drug, the
resistant CD49f+ population shrinks and taxane sensitivity is restored. We describe a transcriptional signature of resistance, predictive of
recurrent disease after chemotherapy in TNBC. Together, these findings identify a CD49f+ population enriched in tumor-initiating ability
and chemoresistance properties and evidence a drug holiday effect on the acquired resistance to docetaxel in triple-negative breast cancer.INTRODUCTION
Triple-negative breast cancer (TNBC) is a heterogeneous
disease with divergent profiles of chemosensitivity and
prognosis (Perou et al., 2000; Prat et al., 2010; Shah et al.,
2012; Yu et al., 2013). Standard chemotherapywith anthra-
cyclines and taxanes is the mainstay treatment. A subset of
TNBCs shows increased chemosensitivity compared with
other breast cancer subtypes; however, for a significant
number of patients, overall prognosis is poorer, with high
risk of early relapse. Once metastases appear the patient
median survival is drastically reduced (Andre and Zielinski,
2012). Despite enormous efforts, the cause of resistance to
chemotherapy agents, including taxanes, is unclear (Bon-
nefoi et al., 2011). There remains an urgent unmet need
to identify the population of patients that will benefit
from taxanes, on one hand, and to determine the mecha-
nisms of resistance, on the other.1392 Stem Cell Reports j Vol. 8 j 1392–1407 j May 9, 2017 j ª 2017 The Aut
This is an open access article under the CC BY-NC-ND license (http://creativThere is increasing evidence that in a variety of neoplasia,
including breast cancer, only a subset of cancer cells are
capable of reconstituting the tumor after transplantation.
These cells called cancer stem cells (CSCs) or tumor-initi-
ating cells (TICs), have the ability to self-renew and regen-
erate tumor heterogeneity (Al-Hajj et al., 2003) and show
intrinsic resistance to conventional chemotherapies, lead-
ing to recurrence or metastasis. In fact, breast tumors
from patients who received neoadjuvant chemotherapy
are substantially enriched for CSCs compared with tumors
of untreated patients (Yu et al., 2007), suggesting that anti-
cancer agents kill the bulk of tumor cells, but spare the
CSCs (Dean et al., 2005). In breast cancer, a variety of
markers (CD44, CD24, EpCAM, CD49f, CD133/2, CD10,
and ALDH activity) have been shown to identify CSCs
(Al-Hajj et al., 2003; Bachelard-Cascales et al., 2008; Li
et al., 2008; Lim et al., 2009; Stingl et al., 2006). However,





















































































































































Figure 1. Generation and Characterization of PDX Models of Human Breast Cancer
(A) Percentage of palpable tumors that engrafted relative to total number of independent patient samples, classified by subtype and
source. The total number of original patient samples is indicated and mice that did not survive for at least 60 days after surgery were
excluded.
(B) Tumor latency in IDB-01 at the indicated passages. Total number of tumors (n), mean, SD, and t test p values are shown.
****p < 0.0001.
(legend continued on next page)
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for the different breast cancer subtypes, and further studies
are necessary to identify the population of TICs and their
functionality in each type of tumors.
The lack of appropriate tools and models has hindered
our efforts to gain insight into the mechanisms of drug
resistance. The best approach to investigate acquired resis-
tance requires analysis of primary or metastatic samples
collected before and after recurrence, but these paired sen-
sitive/resistant samples are often difficult to obtain. To
advance our knowledge in clinical breast cancer and the
molecular mechanisms of resistance, we have generated
breast cancer patient-derived orthoxenografts (PDXs),
which allow the amplification and perpetuation of hu-
man tumors by serial passages. Our panel of breast cancer
PDXs recapitulates the heterogeneity of the clinical dis-
ease and constitutes a unique tool for studying the biolog-
ical mechanisms of clinical response to taxanes and acqui-
sition of resistance. We demonstrate that a CD49f+ cell
population with tumor-initiating ability and increased
resistance to taxanes is present in the initially sensitive
TNBC tumors and expands during continued exposure
to the drug in vivo, contributing to taxane resistance
and tumor recurrence. Remarkably, the transcriptional
differences observed between the CD49f+ population of
sensitive and resistant tumors accompany and may
contribute to the acquisition of chemoresistance. Finally,
we demonstrate that docetaxel sensitivity is recovered in
the absence of the drug and associates with changes in
the CD49f+ population.RESULTS
PDX Models Resemble Human Tumors of Origin in
Early Passages
PDX were generated as described (DeRose et al., 2011;
Zhang et al., 2013; Table S1). Increased tumor rates and
shorter latency to tumor formation was observed in sam-
ples derived from pleural effusions compared with tumor
pieces. The TNBC engrafted better than luminal tumors
and all palpable tumors derived from grade 3 human sam-
ples (Figures 1A, S1A, and S1B). Of the mammary glands,
52% with no palpable tumor contained human mam-
mary epithelium, mostly normal ducts and grade 1 intra-
ductal carcinoma indicating engraftment of these low-
grade lesions (Figures S1C and S1D; Table S1). Tumor lines
(Table 1, yellow in Table S1) were maintained by consec-(C) Tumor growth in IDB-01, calculated as L 3 I (mm 3 mm)/100 ve
(D) Unsupervised clustering using the PAM50 genes across the PDX
clinical samples (Prat et al., 2015b). The type of sample and the subtyp
transcript abundance. All PDX tumors were from passage 5.
See also Table S1; Figures S1 and S2.
1394 Stem Cell Reports j Vol. 8 j 1392–1407 j May 9, 2017utive rounds of transplantation, and include two TNBC
models derived from pleural effusions, the second one a
BRCA1 mutant (IDB-01, IDB-02); two luminal/HER2-
negative models (IDB-03 and IDB-04) derived from tumor
pieces and pleural effusion, respectively; and one (IDB-
05) derived from a tumor piece of a triple-positive (ER+
PR+ HER2+) breast cancer. In most models, shorter la-
tency and faster tumor growth were observed in late pas-
sages (Figures 1B, 1C, S1E, and S1F). Thus, as demon-
strated previously (DeRose et al., 2011; Dobrolecki et al.,
2016; Zhang et al., 2013), establishment of PDX models
was associated with increased tumor aggressiveness and
poor prognosis.
Expression analyses of markers used in the clinical
setting for histopathological tumor classification and selec-
tion of treatment (ER, PR, HER2, CK5/6, CK18, and p53), in
parental human tumors and PDX tumors at early (0–1) and
late passages (4–8) demonstrate that PDX retain most hu-
man characteristics in the early passages, but occasional
changes are observed in some models (Table 1; Figures
S1G and S2A). ER and PR mRNA and protein expression
was detected in tumors from all passages of the luminal
models IDB-04 and IDB-05 (Figures S2A and S1G), but
only IDB-05 required estrogen/progesterone pellets to
grow (Figure S1H). IDB-03, ER+ and PR+ in the patient,
lost ER and PR expression in the PDX and a population of
p53+ cells was enriched (Table 1; Figure S2A and S1G). After
surgically resection of tumors, most models developed
local relapses andmetastases to clinical relevant sites (Table
1; Figure S2B).
Next, we performed intrinsic subtyping of our 5 PDX
models and their corresponding human tumors of origin
using the PAM50 subtype predictor (Parker et al., 2009),
and clustered these samples with 1,834 breast tumor
samples representing all subtypes (Prat et al., 2015b).
Mimicking the intrinsic subtypes of their corresponding
human tumors, the two TNBC models were identified as
basal-like, IDB-04 (HR+/HER2–) as luminal B, and the
HER2+ IDB-05 as HER2 enriched (HER2-E). Interestingly,
the human tumor of origin for IDB-03 was identified
as luminal B but the PDX was identified as HER2-E by
PAM50 without HER2 overexpression (Figure 1D). As re-
ported in similar PDX collections (Dobrolecki et al.,
2016), our mouse grafts retain initial human tumor char-
acteristics, but some models change during serial passages
in mice, which may reflect evolution of the clinical
disease.rsus time (weeks). Each line represents a representative tumor.
models, human tumors of origin, and 1,834 human breast cancer
e call of each sample are shown. Each square represents the relative
Table 1. Main Characteristics of Human Tumor of Origin and Mouse Grafts in Five Established IDB Models


























no change no change loss of ER
and PR
no change no change
passage 13 8 16 7 9
latency (p5) (days) 19 42 18 63 27
growth without
hormone pellets
yes yes yes yes no
Local relapse (%) 17.24 (n = 116) 6.94 (n = 144) 20.79 (n = 178) 23.40 (n = 94) 8.54 (n = 94)
axillary metastasis (%) 10 10 46 0 8
lymph ND
metastasis (%)
14 33 41.2 0 50
lung metastasis (%) 20 20 10 0 20
metastasis to other
sites




















source pleural pleural tumor pieces pleural tumor pieces
treatment FEC, docetaxel,
capecitabine
FEC, docetaxel not treated paclitaxel, carboplatin,
capecitabine
not treated
ER, estrogen receptor; PR, progesterone receptor; CK, cytokeratin, FEC, triple treatment composed of 5-fluorouracil, epirubicin and cyclophosphamide.
Frequency of tumor relapse per mammary gland (local relapse) and metastasis is indicated in each model. Only mice that survived for at least 60 days after
primary tumor excision with no relapse/metastasis were considered as relapse/metastasis free. All metastases were confirmed by pathologists. ND, not deter-
mined. See also Table S1.Basal-like PDX Are Initially Sensitive to Docetaxel but
Acquire Resistance after Continuous Exposure to the
Drug In Vivo
Next, we tested the sensitivity of orthotopic mouse
models to docetaxel, one of the most commonly used che-
motherapeutics in breast cancer and other solid tumors
(Figure S3A). According to docetaxel response, tumors
were classified as sensitive when the treatment induced
complete tumor regression; partially sensitive when the
treatment interfered with tumor growth inducing com-
plete regression in some tumors but not in others; and resis-
tant when tumors continued growing despite docetaxel
treatment. In line with these criteria, luminal tumors
from IDB-03 and IDB-04 were resistant to docetaxel, the
TNBC IDB-01 model was sensitive (IDB-01S), and the
TNBC IDB-02 was partially sensitive to the drug (Figures2A, 2B, and S3B). Despite the initial pathological complete
response, all IDB-01 tumors started growing again
30–60 days after treatment interruption. In the second
round of treatment, more doses of docetaxel were required
to eliminate tumors and a more heterogeneous response
between individual tumors was observed (partially sensi-
tive tumors). This behavior was accentuated during consec-
utive docetaxel treatments and the tumors became resis-
tant in passage 3 (Figures 2B and 2C). Resistance was
retained for at least two passages in the absence of doce-
taxel, as IDB-01-resistant tumors (IDB-01R, passage 5)
grew at comparable growth rates irrespective of docetaxel
treatment (Figure 2D). Importantly, tumors growing
without the selective pressure of docetaxel partially re-
gained sensitivity after five passages (IDB-01R, passage 8),
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(Figure 2D). No differences in latency to tumor formation
or tumor growthwere observed between IDB-01S (sensitive
tumors of origin) and the resistant ones, IDB-01R, derived
from them (Figures S3C and S3D). Gene expression ana-
lyses of IDB-01S and IDB-01R tumors identified a signature
(22 downregulated genes in IDB-01R) that was predictive of
residual disease after anthracycline/taxane-based therapy
in 166 patients with basal-like disease (GSE25066) (Hatzis
et al., 2011) and poor survival in the TCGA dataset, high-
lighting the clinical relevance of our sensitive and resistant
PDX pairs (Figures 2E, 2F, and S3E). In IDB-02 an already
heterogeneous response was observed after the first doses,
and docetaxel treatment could not be interrupted in most
mice (Figures 2B, 2C, and S3B). Tumors started growing
very fast after interruption of the treatment and became
resistant in passage 2. A third passage and additional doce-
taxel treatments did not change tumor growth, demon-
strating that tumors had acquired resistance to docetaxel,
which was retained for at least two passages (Figures 2B–
2D). IDB-02R resistant tumors showed similar latency as
IDB-02S sensitive tumors but grew significantly faster (Fig-
ures S3C and S3D). These results demonstrate that our tri-
ple-negative PDX tumors are more sensitive to docetaxel
than the luminal ones. In the clinic, a better response to
chemotherapy is observed in TNBC compared with
luminal tumors, and in some studies taxanes have been
shown to be superior to anthracyclines in this subtype
(Kim et al., 2010; Martin et al., 2011). Moreover, initially
sensitive PDX tumors gradually became less responsive to
docetaxel and acquired resistance after continuous expo-
sure to the drug, mimicking the clinical scenario.
Docetaxel Acquired Resistance Is Accompanied by an
Increase in the CD49f+ Population
It has been shown that chemotherapy efficiently elimi-
nates the bulk tumor cells but spares the CSC populationFigure 2. TNBC PDX Tumors were Sensitive to Docetaxel and Acquir
Tumors were Resistant
(A) Representative kinetics of tumor growth during docetaxel treatmen
tumors reached 6 3 6 mm. Each line illustrates a representative tum
(B) Percentage of sensitive, partially sensitive or resistant tumors of e
indicated.
(C) Representative kinetics of tumor growth during acquisition of res
represents one tumor and each color represents an independent sensi
indicate the tumors that were transplanted.
(D) Representative kinetics of tumor growth during docetaxel treatmen
tumor. IDB-01R tumors were analyzed after growing for two and five
(E) Supervised expression analysis of the genes found differentially
resents the relative transcript abundance.
(F) Association of IDB-01 resistant signature with chemotherapy res
2011). Response was measured as pathological complete response (pC
max) and t test p values are shown.
(A, C, and D) Arrows represent docetaxel doses. See also Figure S3.(Li et al., 2008). Thus, we analyzed the expression of
markers previously shown to identify CSCs in our PDX tu-
mor collection including paired sensitive and resistant tu-
mors from IDB-01 and IDB-02 (Figure S4A-B). Variability
in marker expression was detected between models with
the same histological and molecular subtype. Docetaxel-
resistant luminal tumors (IDB-03 and IDB-04) showed the
highest percentages of EpCAM, CD49f, and CD24 cells,
but the CD133 population was scarce. IDB-03 contained
an abundant CD44+ population and ALDH activity, and
is the only one expressing CD10. A CD133+ population
was found in basal-like and HER2+ PDX. The CD44+
CD24– population, shown to identify human breast
CSCs (Al-Hajj et al., 2003), was only detected in the
TNBC IDB-02 (Figures S4B and S4C).
No significant changes in the expression of CD44,
CD24, CD133, or CD10 were found between sensitive
and resistant TNBC paired samples, neither in IDB-01 nor
in IDB-02. The CD44+ CD24– population remained barely
detectable in the chemoresistant models, and the ALDH+
population, based on ALDH enzymatic activity, was also
comparable between paired sensitive and resistant tumors
(Figure 3A). In contrast, the frequency of CD49f+ cells
significantly increased in TNBC-resistant tumors compared
with paired sensitive ones in both models. A significant in-
crease in the frequency of EpCAM+ cells was also observed
in IDB-01R compared with IDB-01S tumors (Figure 3A).
Resistant tumors from IDB-01 and IDB-02 showed signifi-
cantly higher mRNA expression levels of CD49f (ITGA6)
but not EpCAM, than the corresponding sensitive tumors
(Figure 3B).
We next sought to investigate the clinical relevance of
our findings by analyzing different clinical datasets. In
basal-like tumors from the EORTC 10994/BIG-1-00 clinical
trial (Bonnefoi et al., 2011), higher expression of CD49f
and EpCAM was associated with a non-pathologicaled Resistance after Continuous Treatment, whereas the Luminal
t. Docetaxel treatment (20 mg/kg i.p., once per week) started when
or (passages 4–14).
ach model to docetaxel. Total number of tumors (n) and passage are
istance to docetaxel in the basal-like IDB-01 and IDB-02. Each line
tive tumor of origin. Ps, passage treated with docetaxel. Red circles
t after acquisition of resistance to taxanes. Each line represents one
passages, respectively, in the absence of docetaxel.
expressed between IDB-01R and IDB-01S tumors. Each square rep-
ponse in 166 patients with basal-like breast cancer (Hatzis et al.,
R) or residual disease (RD). Mean values, box and whiskers (min to
Stem Cell Reports j Vol. 8 j 1392–1407 j May 9, 2017 1397
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HR = 3.06 (0.97 − 9.63)
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HR = 1.21 (0.44 − 3.33)
logrank P = 0.72






















Figure 3. The CD49f+ Population Is Enriched after Acquisition of Resistance to Docetaxel
(A) Frequency of indicated markers within the H2Kd– population in IDB-01 and IDB-02, sensitive and resistant tumors analyzed by flow
cytometry at passage 3, at least 5 days after the last docetaxel treatment. Total number of tumors analyzed (n) mean values, SDs and t test
p values are shown. *0.01 < p < 0.05; **0.001 < p < 0.01.
(B) Box and whiskers (min to max) graph showing expression levels of CD49f and EpCAM mRNA relative to PPiA in additional sensitive and
resistant tumors measured by qRT-PCR. Determinations were done in triplicate and means are used. t test p values for significant dif-
ferences are shown. **0.001 < p < 0.01.
(C) Box and whiskers (min to max) graph showing association of CD49f and EpCAM with chemotherapy response in 74 patients with basal-
like breast cancer EORTC (Bonnefoi et al., 2011). Response was measured as pathological complete response (pCR) or residual disease (RD).
t test p values are shown.
(D) Kaplan-Meier analysis of overall survival of ER-tumors all treated with chemotherapy using CD49f and EpCAM mRNA expression in the
clinical dataset (GSE16446) from the TOP TRIAL (Desmedt et al., 2011).
See also Figures S3 and S4.
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Figure 4. CD49f Expression Increases in Residual Disease of Most TNBC PDX Tumors after Treatment with Docetaxel, but Not on
Resistant Tumors
(A) Scheme of short-term docetaxel treatment and CD49f mRNA expression levels in sensitive tumors from IDB-01S and IDB-02S
after short-term treatment with docetaxel (DTX) and in untreated controls (CT). Each dot represents one tumor. *0.01 < p < 0.05; **0.001 <
p < 0.01.
(B) Frequency of CD49f+ cells within H2Kd– in IDB-01S tumors after two to three doses of docetaxel and in IDB-01R tumors that have
been treated with docetaxel (at least 5 days after last treatment) or growing in the absence of docetaxel for two and five passages. *0.01 <
p < 0.05; **0.001 < p < 0.01.
(legend continued on next page)
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complete response (non-pCR) after chemotherapy (Fig-
ure 3C). UsingGOBO, theGene expression-basedOutcome
for Breast cancer Online tool (Ringner et al., 2011), high
expression levels of EpCAM and CD49f combined
predicted a reduction in distal metastasis-free survival in
basal-like tumors (Figure S3F). Associations with poor over-
all survival were obtained for CD49f, but not EpCAM, in
other ER-negative or basal-like tumor samples after chemo-
therapy treatment (Clarke et al., 2013; Desmedt et al.,
2011) (Figures 3D, S3G, and S3H). These results demon-
strate that, whereas CD44+ CD24– and ALDH activity are
not altered, the percentage of the CD49f+ population
significantly increases during the acquisition of resistance
to docetaxel in basal-like breast cancer.
A Chemoresistant CD49f+ Population Is Present in
Most TNBC Tumors
We hypothesized that a chemoresistant CD49f+ popula-
tion is present in the original sensitive tumors. To test
this hypothesis we analyzed CD49f mRNA expression in
IDB-01S and IDB-02S tumors after two to three doses of do-
cetaxel treatment when tumors were shrinking, and found
a significant increase in CD49fmRNA expression in the re-
sidual disease of both PDX tumors (Figure 4A). Next, we
evaluated by flow cytometry the percentage of cells ex-
pressing CD49f in residual disease and found that the fre-
quency of CD49f+ cells in residual disease of IDB-01S after
docetaxel treatment increases by 20%; these levels are com-
parable with those of resistant IDB-01R tumors, indicating
that the surviving population is enriched in CD49f+ cells
(Figure 4B). Importantly, in IDB-01R tumors that regained
sensitivity to taxanes after growing in the absence of doce-
taxel (passage 8), the frequency of the CD49f+ population
decreases again to basal levels, similar to those found in
sensitive tumors of origin (Figure 4B).
To evaluate whether a chemoresistant CD49f+ popula-
tion could be found in other TNBC tumors, we analyzed
CD49f expression after short-term in vivo treatment with
docetaxel in 12 additional TNBC PDX tumors derived
from patient samples (Bruna et al., 2016; DeRose et al.,
2011). Four of these PDX tumorswere resistant to docetaxel
(no differences in tumor growth after docetaxel treatment),
and eight showed different grades of sensitivity to the drug
(tumors either shrank or showed tumor growth stabiliza-
tion after two to four doses of docetaxel). After docetaxel
treatment, an increase in CD49f mRNA expression levels(C and D) Docetaxel-sensitive tumors (C) and docetaxel-resistant tum
with docetaxel (20 mg/kg, arrows) and corresponding controls relative
****p < 0.0001. Bottom panels: CD49f mRNA expression levels in PDX
controls. Each dot represents one tumor. *0.01 < p < 0.05; **0.001 <
(A–D) Mean values, SEM, and t test p values are shown in all cases.
See also Figure S5.
1400 Stem Cell Reports j Vol. 8 j 1392–1407 j May 9, 2017was observed in residual disease of five out of the eight
TNBC-sensitive tumors treated, whereas in resistant tumors
CD49f expression remained unaltered (Figures 4C, 4D,
and S5A). No changes in the expression of the most
common partners of CD49f, CD29 (ITGB1) and CD104
(ITGB4), were observed between sensitive, resistant and
residual disease in TNBC tumors (Figure S5B-D). The in-
crease in CD49f expression in residual tumors suggests
that CD49f+ chemoresistant cells are present in doce-
taxel-sensitive tumors and get enriched in residual disease.
In addition, we analyzed CD49fmRNA expression in five
independent TNBC cell lines after 72 h of treatment with
increasing concentrations of docetaxel. Different cell lines
showed different grades of sensitivity to taxanes but, in
four out of the five cell lines tested, a significant increase
in CD49f mRNA expression was found in cells that survive
docetaxel treatment compared with the untreated ones
(Figure 5A). No changes inCD49f expressionwere observed
at shorter time points with negligible cell death, suggesting
that docetaxel does not induce CD49f expression and that
the observed increase in residual disease, most probably
represents the survival of a pre-existing CD49f+ population
(Figure 5B). Higher levels of CD49f mRNA after paclitaxel
treatmentwere also observed in some cell lines (Figure S5E).
No changes in docetaxel sensitivity were observed inMDA-
MB-436 cells upon stable reduction of CD49f expression
with two independent short hairpin RNA constructs, ruling
out a functional role for CD49f itself in chemoresistance of
these cells (Figures 5C–5E and S5F).
Together these results demonstrate that higher expres-
sion of CD49f was observed in residual disease after doce-
taxel treatment for most TNBC-sensitive models (seven
out of ten PDX models and four out of five cell lines), sug-
gesting that despite the heterogeneity of the TNBC subtype
a chemoresistant CD49f+ population is present in most
TNBC.
CD49f+/hi Cells Show Enhanced Tumor-Initiating
Ability and Resistance to Docetaxel
Next, we asked whether chemoresistant CD49f+ cells
showed a higher tumor-initiating potential than CD49f
cells and could be responsible for tumor recurrence. Using
fluorescence-activated cell sorting (FACS), we sorted the
higher and lower quartile of tumor cells based on CD49f
expression fromIDB-01S and IDB-02S tumors and function-
ally tested their tumor-initiating potential (Figure 6A).ors (D). Top panels: tumor size of the indicated PDX tumors treated
to the size at the first day of treatment. n = total number of tumors.
tumors after short-term treatment with docetaxel and in untreated
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Figure 5. CD49f Expression Increases in Surviving TNBC Cells after Treatment with Docetaxel
(A and B) Top panels: percentage of surviving cells treated with docetaxel for 72 h (A) or 8 h (B). Bottom panels: CD49f mRNA expression
levels in the indicated TNBC cell lines treated with docetaxel relative to untreated controls. *0.01 < p < 0.05; **0.001 < p < 0.01;
***0.001 < p < 0.0001.
(legend continued on next page)
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Indeed, only CD49f+/hi cells, but not the CD49f in
the IDB-01S model, were able to give rise to tumors when
re-implanted in mice (Figure 6B). Tumors derived from
the IDB-01S-CD49f+/hi cells contained a more abundant
CD49f+ population, but also CD49f– cells demonstrating
that the tumor-initiating CD49f+/hi cells were able to give
rise to non-TICs CD49f cells (Figure 6C). Docetaxel atten-
uated growth in tumors derived from IDB-01S-CD49f+/hi
cells, but tumors were still palpable after ten doses of doce-
taxel, in contrast to sensitive tumors of origin IDB-01S that
were not detectable after four doses (Figure 6D). Thus, IDB-
01S-CD49f+/hi derived tumors are more resistant to doce-
taxel than the original IDB-01S tumors.
In IDB-02, where tumors were partially sensitive to
docetaxel and contained a higher proportion of CD49f+
cells, bothCD49f+/hi andCD49f cells gave rise to tumors.
However, limiting dilution assays and extreme limiting
dilution analyses (ELDA) revealed that the CD49f+/hi pop-
ulation showed a 5-fold increase in tumor-initiating ability
compared with the CD49f cells (Figure 6E). In addition,
the CD49f+/hi cells gave rise to tumors with shorter
latency than CD49f cells (Figure 6F). CD49f+ cells
were more abundant in CD49f+/hi than in tumors derived
from CD49f, but tumors from both groups contained
CD49f+ and CD49f cells (Figure 6G), demonstrating that
CD49f cells can also give rise to CD49f+ cells. Again,
IDB-02S-CD49f/lo-derived tumors were more sensitive
to docetaxel than the ones derived from IDB-02S-CD49f+
cells (Figure 6H).
Unsupervised gene expression profiling of FACS-sorted
CD49f+/hi and CD49f cells from IDB-01S and -01R, us-
ing 105 breast cancer-selected genes, revealed twomain clus-
ters which broadly represents the CD49f+ and CD49f pop-
ulations (Figures 6I and S6A). Compared with CD49f cells,
CD49f+ cells showed downregulation of keratins, claudins
and CDH3, and upregulation of SFRP1, MIA and prolifera-
tion-related genes (UBE2C, CDC6 and CDC20) (Figure 6I).
Further gene expression analyses revealed significant tran-
scriptome differences between CD49f+/hi cells from resis-
tant and sensitive tumors, including enhanced decrease in
tight junctionproteins, claudins, andCDH3,whichmaysug-
gest amore claudin-lowphenotype (Prat et al., 2010).Down-
regulation of tumor suppressors (e.g., PTEN and RAB25) is
also observed in CD49f+ cells from resistant tumors (Fig-
ure S6A). Interestingly, CD49f+/hi cells showed increased
proliferation by gene expression analysis thanCD49f cells,
especially within sensitive tumors (Figure S6B). Among the(C and D) CD49f mRNA expression levels (C) and CD49f protein expressi
independent shCD49f knockdown constructs and control vector (pGIP
(E) Percentage of surviving shCD49f-infected and control pGIPZ-infec
RT-PCR Determinations were done in triplicate and means are used in
SEM, and t test p values for the higher concentrations are shown. Se
1402 Stem Cell Reports j Vol. 8 j 1392–1407 j May 9, 2017two CD49f+ signatures, the IDB-01R/CD49f+ signature was
found to predict residual disease following anthracycline/
taxane-based therapy in breast tumors (GSE25066), concor-
dant with our preclinical observations (Figure S6C). On
the other hand, the IDB-01S/CD49f+ signature was found
to predict pathological complete response (pCR) following
anthracycline/taxane-based therapy, likely due to the large
difference in proliferation between CD49f+ and CD49f
cells in IDB-01S tumors (Figures S6B and S6C) (Hatzis et al.,
2011). The IDB-01S/CD49f+ signature was associated with
lower recurrence-free survival in an additional dataset
of breast cancer patients (Prat et al., 2010) (Figure S6D).
Together, these results demonstrate that sensitive tumors
of origin contain a tumorigenic and docetaxel-resistant
CD49f+ population that changes and expands during the
acquisition of taxane resistance; whereas in the absence of
the drug, the CD49f+ chemoresistant population shrinks
and taxane sensitivity is restored.DISCUSSION
Patient-derived xenograft (PDX)models have emerged as an
important intermediate toolbetweenbasic researchandclin-
ical trials to expedite the translation of basic research find-
ings into effective therapies for patients. We have generated
a panel of PDX models that recapitulates the heterogeneity
of human breast tumors. Initial collections of breast PDX
were reported to remain phenotypically identical to human
tumors during serial passages (DeRose et al., 2011; Zhang
et al., 2013). However, in agreementwith our findings, there
is increasing evidence that tumors in PDX are not ‘‘static’’
and can evolve, as observed in patients (Eirew et al., 2015).
Our PDX models constitute a unique tool to investigate
resistance in cancer as they mimic clinical responses:
TNBC tumors are more sensitive to chemotherapy than
the luminal tumors, confirming previous clinical results
(Berry et al., 2006; Colleoni et al., 2004; Guarneri et al.,
2006;Martin et al., 2011), and even initially sensitive tumors
develop resistance upon continuous exposure to taxanes.
Both basal-like tumors (IDB-01 and IDB-02) derived from
metastatic samples that were heavily exposed to multiple
treatments including taxanes showed minimal clinical
response. Strikingly, sensitivity to docetaxel was restored
upon xenografting and was retained for months. Moreover,
we observed that in PDX tumors with acquired resistance,
sensitivity is partially restored when maintained in theon measured by flow cytometry (D) in cells stably infected with two
Z).
ted cells treated with indicated doses of docetaxel for 72 hr.
the calculations. Mean values of three independent experiments,
e also Figure S5.
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Figure 6. CD49f+ Population Is Enriched in Tumor-Initiating Cells with Increased Resistance to Docetaxel
(A) Scheme of functional experiments.
(B and E) Table showing limiting dilution assay of CD49f+/hi and CD49f tumor cells from IDB-01 (B) and IDB-02 (E) cells. Tumor-initiating
cell frequency (with confidence intervals) for each group was calculated by ELDA; chi-square values and associated probabilities are shown.
(legend continued on next page)
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absence of the drug. This regain of sensitivity, the so-called
‘‘drug holiday,’’ has been described for targeted therapies in
melanoma (Das Thakur et al., 2013; Sun et al., 2014). We
now demonstrate that the same is true for cytotoxics such
as docetaxel, with important implications for clinical deci-
sions and drug scheduling, as resistant metastatic disease
may benefit from intermittent docetaxel treatment.
Our data demonstrate that a pre-existing and chemore-
sistant CD49f+ subpopulation is present in most sensitive
TNBC, expands during long-term therapy, and has the abil-
ity to generate novel tumors contributing to recurrence and
acquisition of chemoresistance (as shown in the graphical
abstract), and importantly that this population shrinks
again in the absence of taxanes, restoring drug sensitivity.
Previous reports have also shown the increased tumor-initi-
ating ability of CD49f+ cells in breast and other solid tu-
mors (Haraguchi et al., 2013; Lo et al., 2012; Meyer et al.,
2010; Vassilopoulos et al., 2014). These findings do not
imply that the CD49f+ cells are the CSC in TNBC, but
demonstrate that the CD49f+ population is associated
with taxane resistance.
Aiming to further characterize the chemoresistant
CD49f+ population, an unbiased approach was under-
taken. Gene expression analysis revealed important differ-
ences, not only between CD49f+ and CD49f cells, but
also between CD49f+ cells from sensitive and resistant tu-
mors. These changes may suggest that the chemoresistant
CD49f+ population has expanded during the exposure to
docetaxel, and can provide novel therapeutic targets for
the metastatic chemoresistant basal-like tumors. Given
the heterogeneity of the TNBC subtype, the significant in-
crease in CD49f expression observed in residual or stabi-
lized disease of most TNBC cell lines and PDX models is
remarkable and indicates that modulation of CD49f posi-
tivity as a biomarker of taxane resistance is not a peculiarity
of a single PDX model but a general event in TNBC, which
can be exploited for clinical benefit.
These findings can be clinically validated in the neoadju-
vant setting, evaluating whether an enrichment of the
CD49f population is observed in residual disease following
taxane-based chemotherapy. However, as the rates of pCR
in TNBC are high (30%–40%), a dynamic study of early
changes in the CD49f population after the first cycles of(C and G) Frequency of CD49f+ cells in tumors derived from indicated
**0.001 < p < 0.01; ***0.001 < p < 0.0001.
(D and H) Kinetics of tumor growth during docetaxel treatment in tumo
are shown. **0.001 < p < 0.01; ****p <0.0001.
(F) Latency of tumors derived from the injection of the indicated numb
SEM and significant t test p values are shown. **0.001 < p < 0.01.
(I) Unsupervised analysis of all CD49f sorted samples from IDB-01S a
sample and tumor are shown below the array tree. Each square repres
See also Figure S6.
1404 Stem Cell Reports j Vol. 8 j 1392–1407 j May 9, 2017taxane treatment and occurrence of pCR could be a
better approach. The clinical utility of the biomarker
could be tested in a prospective clinical trial in the neoadju-
vant setting where patients are randomized based on the
biomarker modulation to change treatment or continue
with taxane-based therapy. Improvement of clinical out-
comes (pCR rates or survival) should be the final objective.
The effect of novel drugs can be evaluated in the subgroup
of chemoresistant CD49f-enriched TNBC. In clinical series
the presence of CD49f+ in breast cancer is associated with
a poor clinical outcome (Friedrichs et al., 1995; Ye et al.,
2015). Moreover, within several CSC markers (CD44,
CD24, ALDH1A3, and CD49f) analyzed by IHC in breast
cancer samples, only CD49f retained prognostic value in a
multivariate analyses in ER– disease (Ali et al., 2011).Our re-
sults provide a functional rationale for the poor outcome
associated with CD49f expression in hormone receptor-
negative breast cancer. Further studies will reveal whether
this population can be manipulated in order to unveil the
ever-elusive status of tumor drug resistance and recurrence.EXPERIMENTAL PROCEDURES
Patient Characteristics and Generation of PDX
IDB PDX were generated by orthotopic transplantation of primary
tumor pieces obtained directly after surgery or cancer cells isolated
from pleural effusions and transplanted into the fat pad of immu-
nodeficientmice, as described previously (DeRose et al., 2011). The
clinical characteristics from original patient samples, the number
and strain of recipient mice, and the outcome of the implant are
indicated in Table S1 (IDB-01-05models). All experimental proced-
ures were performed according to Spanish regulations. Informed
consent was obtained from all subjects and the study received
approval from the institutional Ethics Committee. Additional
models were generated following similar procedures (Bruna et al.,
2016). All research involving animals was performed at the IDI-
BELL animal facility in compliance with protocols approved by
the IDIBELL Committee on Animal Care and following national
and European Union regulations.
Breast Cancer Cell Isolation, Flow Cytometry, and
Sorting
Single cells were isolated from tumors as described previously
(Smalley, 2010). Single cells were resuspended and blocked withcells. Mean values, SEM, and significant t test p values are shown.
rs derived from indicated cells. Mean values, SEM, and t test p values
er of IDB-02S-CD49f+/hi and 02S-CD49f tumor cells. Mean values,
nd -01R tumors using 105 breast cancer-related genes. The type of
ents the relative transcript abundance.
PBS 2% fetal bovine serum (FBS), 2 mM EDTA, and immunoglob-
ulin G blocking reagent for 10 min on ice. Then they were labeled
with antibodies against CD24-PE (555428), CD44-APC (559942),
EpCAM-FITC (347197), CD10-PECy5 (555376), and CD49f-A647
(562473) (all from BD Pharmingen), CD133/1-PE (130-098-826
fromMiltenyi Biotec), andCD49f-APC (FAB13501A fromR&DSys-
tems). Mouse cells were excluded in flow cytometry using H2Kd-
PECy7 (116622 from BioLegend). Gating was based on ‘‘Fluores-
cence Minus One’’ controls. Single cells were assessed for their
ALDH activity using the ALDEFLUOR assay system (01700 from
STEMCELL Technologies) following the manufacturer’s proced-
ures. A population of 10,000 living cells was captured in all FACS
experiments. FACS analysis and sorting was performed using Gal-
lios and MoFlo (Beckman Coulter) flow cytometers, respectively.
Data was analyzed using the FlowJo software (see Figure S4).
Therapeutic and Limiting Dilution Assays
Docetaxel (Hospira/Actavis, 20 mg/kg) was administered intraperi-
toneally once per week (unless reported otherwise), followed 24 hr
later by Fortecortin (Dexametasona, 0.132 mg/kg, Merck). The
treatment scheme of resistant variants generation is shown in Fig-
ure S3. For orthotopic ELDA, isolated tumor cells were mixed 1:1
with Matrigel Basement Membrane (BD Biosciences) and ortho-
topically implanted in the inguinal mammary gland of non-obese
diabetic/severe combined immunodeficiency females. Tumor
development was monitored once per week for a maximum of
25 weeks. In all assays the tumor-initiating potential was defined
as the ability to formpalpable, growing tumors ofR2mmdiameter.
Culture and Treatment of Human Breast Cancer Cells
All cell lines were purchased from the American Type Culture
Collection (Rockville, MD), except for UACC3199 which was ob-
tained from the Arizona Cancer Center (Tucson, AZ). All cells but
HCC1143, which was cultured in RPMI 1640, were maintained
in DMEM high glucose, containing 10% FBS (Gibco), L-glutamate
(Gibco), and penicillin/streptomycin (PAA Laboratories) at 37C in
5% CO2. At 60%–70% confluence the indicated concentrations of
docetaxel or paclitaxel were added. Cells were collected at the indi-
cated time points and counted with trypan blue to exclude dead
ones. All cell lines were routinely tested for mycoplasma, and
were shown to be free of contamination.
Gene Expression-Based Analyses
A minimum of 100 ng of total RNA was used to measure the
expression of 105 breast cancer-related genes and five house-keep-
ing genes using the nCounter platform (Nanostring Technologies).
Data was log base 2 transformed and normalized using five house-
keeping genes (ACTB, MRPL19, PSMC4, RPLP0 and SF3A1). The list
of 105 genes includes genes from the following three signatures:
PAM50 intrinsic subtype predictor (n = 50) (Parker et al., 2009),
claudin-low subtype predictor (n = 43) (Prat et al., 2010),
13-VEGF/hypoxia signature (n = 13) (Hu et al., 2009), and eight in-
dividual genes that have been found to play an important role in
breast cancer (e.g., CD24). Raw gene expression data and
signatures can be found in Table S2. All tumors were assigned
to an intrinsic molecular subtype of breast cancer (luminal A,
luminal B, HER2-enriched, basal-like, and claudin-low) and thenormal-like group using the previously reported PAM50 subtype
and the claudin-low subtype predictors (Parker et al., 2009; Prat
et al., 2010, 2015b).
Gene Expression-Based Signatures
Genes differentially expressed between the two groups were iden-
tified using a two-class unpaired Significance Analysis of Microar-
rays (SAM) (Tusher et al., 2001) and a false discovery rate of <5%.
The final signature of up- and/or downregulated genes was then
summarized as a single ‘‘enrichment/activity score’’ bymultiplying
the SAM score of each gene by its expression value in the tested
sample and then summing all the values of each sample. Each
signature was evaluated in GSE25066, a microarray-based dataset
of patients treated with neoadjuvant anthracycline/taxane-based
chemotherapy (Hatzis et al., 2011) and the Perou-extended dataset
GSE18229 (Prat et al., 2010). This microarray dataset was normal-
ized as described previously (Prat et al., 2015a). Raw data can be
found in Table S2.
Statistical Analyses
All data are expressed as mean ± SEM. Statistical comparison was
performed by Student’s t test using GraphPad Prism version 5.04.
p% 0.05 was considered statistically significant. The statistical sig-
nificance of difference between groups is expressed by asterisks:
*0.01 < p < 0.05; **0.001 < p < 0.01; ***0.001 < p < 0.0001;
****p < 0.0001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, six figures, and two tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
03.026.
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and C. Hierro for providing samples, S. Hernández-Ortega, R. Gil, L.
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